These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38899842)

  • 21. Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis.
    Abdel-Rahman O
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):183-189. PubMed ID: 27830958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The burden of illness associated with hepatocellular carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Shah S; Thompson D
    J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
    Jean RA; Bongiovanni T; Soulos PR; Chiu AS; Herrin J; Kim N; Xu X; Kim AW; Gross CP
    Ann Thorac Surg; 2019 Dec; 108(6):1710-1716. PubMed ID: 31400321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial Comment: Ablation for Early-Stage Hepatocellular Carcinoma Results in Lower Costs Relative to Both Surgical Resection and Transplant.
    Dabiri BE
    AJR Am J Roentgenol; 2024 Aug; 223(2):e2431657. PubMed ID: 39016455
    [No Abstract]   [Full Text] [Related]  

  • 26. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
    McGarvey N; Gitlin M; Fadli E; Chung KC
    J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
    Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
    J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
    Lee S; Kang TW; Cha DI; Song KD; Lee MW; Rhim H; Lim HK; Sinn DH; Kim JM; Kim K
    J Hepatol; 2018 Jul; 69(1):70-78. PubMed ID: 29524532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study.
    Ye QW; Pang SJ; Yang N; Zhang HB; Fu Y; Lin B; Yang GS
    J Gastrointest Surg; 2019 Aug; 23(8):1549-1558. PubMed ID: 31197690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis.
    Miura JT; Johnston FM; Tsai S; Eastwood D; Banerjee A; Christians KK; Turaga KK; Gamblin TC
    HPB (Oxford); 2015 Oct; 17(10):896-901. PubMed ID: 26228076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the effectiveness of surgical resection and ablation for the treatment of early-stage hepatocellular carcinoma: A retrospective cohort study.
    Yang B; Xi X; Yu H; Jiang H; Liang Z; Smayi A; Wu B; Yang Y
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2030. PubMed ID: 38488487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative assessment of the safety and effectiveness of radiofrequency ablation among elderly medicare beneficiaries with hepatocellular carcinoma.
    Massarweh NN; Park JO; Yeung RS; Flum DR
    Ann Surg Oncol; 2012 Apr; 19(4):1058-65. PubMed ID: 21947695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study.
    Ruzzenente A; Guglielmi A; Sandri M; Campagnaro T; Valdegamberi A; Conci S; Bagante F; Turcato G; D'Onofrio M; Iacono C
    J Gastrointest Surg; 2012 Feb; 16(2):301-11; discussion 311. PubMed ID: 22095524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Maithel SK; Cosgrove DP; Pawlik TM
    World J Surg; 2015 Jun; 39(6):1474-84. PubMed ID: 25665675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.
    Kaplan DE; Chapko MK; Mehta R; Dai F; Skanderson M; Aytaman A; Baytarian M; D'Addeo K; Fox R; Hunt K; Pocha C; Valderrama A; Taddei TH;
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):106-114.e5. PubMed ID: 28756056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.